Drug intelligence / Profile preview

ProLumina

Development stage: Unknown
Lead developer: Enactis Healthcare
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

ProLumina is a branded probiotic dietary supplement developed by Enactis Healthcare. [13, 16] It contains 10 billion CFU of the probiotic strain *Lactobacillus plantarum*. [13, 15, 19] ProLumina is marketed for the dietary management of gastrointestinal conditions such as Irritable Bowel Syndrome (IBS), ulcerative colitis, and diarrhea. [13, 17, 21] The proposed mechanism involves restoring the balance of healthy gut bacteria, which helps to improve digestion, reduce gut inflammation, and support overall immune function. [14, 17, 21] It is available as an oral capsule. [13, 15]

Brand names: ProLuminaProLumina™

Beyond the preview

Go deeper on ProLumina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProLumina.

Explore the full profile